Last Saturday, 3.5 million doses of Moderna arrived in Argentina as part of a donation from the Joe Biden government. Since then, the vaccines have been stored in cold without confirmed destination, waiting for the United States Food and Drug Administration (FDA) or the EMA to authorize their use in minors.
The European Medicines Agency (EMA) approved on Friday the use of Moderna’s coronavirus vaccine for adolescents between 12 and 17 years old, which also enabled its application in minors in Argentina, which received 3.5 million of doses of that drug last Saturday.For a long time, parents of children with disabilities or complex health problems have demanded the inoculation of their children.
Last Saturday, 3.5 million doses of Moderna arrived in Argentina as part of a donation from the Joe Biden government. Since then, the vaccines have been stored in cold without confirmed destination, waiting for the United States Food and Drug Administration (FDA) or the EMA to authorize their use in minors, to begin inoculating adolescents between 12 and 17 with comorbidities, a population estimated at 900,000 people in the country.
He grew up in Barrio 31, his efforts took him to Ireland and now he dreams of Harvard
“This authorization enables the beginning in Argentina of vaccination for young people, adolescents and children with risk factors,” reported from the Government shortly after the announcement of the EMA.
Official sources also pointed out that next Tuesday, at a meeting of the Federal Health Council (Cofesa), “the ministers of Health from all over the country will define the groups and the implementation strategy and will formalize the start of vaccination for this prioritized group in all the country”.
According to government projections, the population aged 12 to 17 is approximately 4.25 million adolescents and it is estimated that between 20 and 25 percent may have comorbidities, for which an initial target population of 900,000 adolescents is estimated. . In this sense, around 1.8 million doses of Moderna will be allocated to this group.
Approval in Europe
“The EMA Committee for Medicinal Products for Human Use (CHMP) recommended granting an extension to the covid-19 Spikevax vaccine (formerly known as Covid-19 Vaccine Moderna) to include its use among minors between 12 and 17 years of age,” he stated the European regulator in a statement. It is the second drug authorized for adolescents in the 27 countries of the European Union (EU) after Pfizer.
This vaccine will be administered to adolescents with the same protocol as those over 18, that is, two doses in the muscle of the upper arm, four weeks apart.
— EU Medicines Agency (@EMA_News) July 23, 2021
In the text of the approval, the EMA mentions a study carried out in 3,732 children between 12 and 17 years old and which showed that the vaccine produced an antibody response comparable to that of adults between the ages of 18 and 25 years.
The EMA safety committee added that due to the smaller size of the study, the trial was unable to detect new rare side effects or estimate the risk of known ones, such as myocarditis and pericarditis.
Moderna’s vaccine has messenger RNA (mRNA), a molecule that carries instructions to produce the Spike protein present in the SARS-CoV-2 that causes Covid-19, in order to prepare the body to defend itself in case of being in contact with the virus.
The Pfizer / BioNTech alliance vaccine, which uses the same mRNA technology, had already been licensed from the age of 12 in the United States, Canada and the 27 EU countries.
Adolescents generally develop less severe forms of Covid-19 than older people, but they can become infected and participate in the transmission of the virus. Therefore, their immunization is essential to stop the epidemic, according to experts.
Half of the adults in Europe, 200 million people, are vaccinated against COVID-19, the European Commission declared on Thursday.